Overview

177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs

Status:
Unknown status
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if 68Gallium-octreotate and 18Fluorodesoxyglucose uptake, apparent diffusion coefficient and post 177Lu-octreotate SPECT/CT dosimetry are reliable predictors for lesion-by-lesion treatment outcome.
Phase:
Phase 3
Details
Lead Sponsor:
Jules Bordet Institute
Treatments:
Lutetium Lu 177 dotatate
Octreotide